Sanofi, Regeneron herald more positive PCSK9 data; Durata wins FDA panel nod;

@FierceBiotech: Investors pump $200M into Intarcia's PhIII for once-yearly diabetes therapy. More | Follow @FierceBiotech

@JohnCFierce: Celgene doubles down on Forma with a $600M discovery deal tied to a buyout option. Article | Follow @JohnCFierce

@DamianFierce: On the way home from ACC14? Catch up on the state of the PCSK9 race with our in-depth feature. Read | Follow @DamianFierce

@EmilyMFierce: Committee finds 'scientific misconduct' in blockbuster stem cell papers. News | Follow @EmilyMFierce

> Sanofi ($SNY) and Regeneron ($REGN) are touting positive results from a Japanese Phase II study of alirocumab, their promising PCSK9 inhibitor. News

> Durata Therapeutics ($DRTX) won an FDA panel recommendation for its antibiotic to treat acute bacterial skin infections. More

> The U.K.'s Tiziana Life Sciences is planning to join the wave of European biotech's going public, setting out plans for a $3.3 million IPO. Article

Medical Device News

@FierceMedDev: Covidien's CFO exercised his stock options near the company's 52 week high. Story | Follow @FierceMedDev

@MarkHFierce: Intuitive Surgical's latest da Vinci surgical robot could help it rebound from a challenging year. More | Follow @MarkHFierce

@MichaelGFierce: Wearable data-storing 'electronic skin' could deliver drugs for epilepsy, Parkinson's. Item | Follow @MichaelGFierce

@EmilyWFierce: New paper from researchers at Harvard sheds light on PMA supplement applications for medical devices. Article | Follow @EmilyWFierce

> IPO emigre Lombard Medical looks to raise $60M in a Nasdaq debut. News

> GE Healthcare unit recalls infant warmer systems in China. More

> China's Dehaier Medical continues its turnaround as revenue falls. Story

Pharma News

@FiercePharma: Gilead's Sovaldi triumph puts major hurt on payers' bottom lines. Story | Follow @FiercePharma

@TracyStaton: RT: Today is the first time in my 10 year data that larger cap biotech is trading at the same PE as US pharma. via @MarkSchoenebaum | Follow @TracyStaton

@EricPFierce: GSK attacks African market with combo of goodwill, R&D and plant projects. More | Follow @EricPFierce

@CarlyHFierce: Donald Trump's Twitter tirade blames vaccines for autism increase. News | Follow @CarlyHFierce

> GSK ditches ovarian cancer plans for Votrient. Article

> It's a big win for Eli Lilly in multibillion-dollar Alimta patent fight. Story

> Actavis shells out $100M for Thai generics maker in bid for Southeast Asia growth. More

Biotech Research News

> Committee finds 'scientific misconduct' in blockbuster stem cell papers. News

> Anticancer compound could reverse symptoms of schizophrenia. More

> New molecule could provide relief for autoimmune, inflammatory diseases. Story

> Report: U.S. can do more to support global health R&D. Coverage

> Antioxidant could slow progression of Lou Gehrig's disease, extend lifespan. Article

> NIH opens largest U.S. neuroscience research center. Item

Pharma Manufacturing News

> Bayer will spend $138M to expand its Beijing plant. Story

> GSK sells Indonesia plant even as it boosts commitment there. Article

> Hospira settles investor suit tied to its manufacturing mess-ups. News

> GSK commits $165M toward 5 more plants in Africa. More

> FDA lets Fresenius import saline to help with shortage. Piece

> Regeneron resolves objections to its new Ireland plant. Item

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Combining KSQ's USP1 inhibitor with Merck and AstraZeneca's PARP inhibitor Lynparza was more effective in animal models than either drug on its own.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.